Home
Forms Library
Discovery of Galangin as a Potential DPP-4 Inhibitor That

Discovery of Galangin as a Potential DPP-4 Inhibitor That 2025

Discovery of Galangin as a Potential DPP-4 Inhibitor That Preview on Page 1

See details

4.1 out of 5

24 votes

The dissertation by Amy Elisabeth Rupert focuses on the development of electroosmotic sampling techniques to investigate galanin-degrading ectopeptidase activity in the hippocampus. It presents two sampling designs: a single capillary method and a push-pull electroosmotic sampling approach, both aimed at minimizing tissue damage while allowing for precise fluid collection from brain slice preparations. The study explores the hydrolysis of exogenous galanin following ischemic preconditioning, revealing that pre-conditioned cultures exhibit reduced galanin degradation in specific hippocampal regions. Additionally, it identifies potential ectopeptidases involved in this process and discusses the implications for neuroprotection and therapeutic strategies.

Here's how it works

01. Edit your form online

Type text, add images, blackout confidential details, add comments, highlights and more.

02. Sign it in a few clicks

Draw your signature, type it, upload its image, or use your mobile device as a signature pad.

03. Share your form with others

Send it via email, link, or fax. You can also download it, export it or print it out.

The best way to modify Discovery of Galangin as a Potential DPP-4 Inhibitor That in PDF format online

Ease of Setup

DocHub User Ratings on G2

Ease of Use

DocHub User Ratings on G2

Adjusting documents with our comprehensive and intuitive PDF editor is straightforward. Follow the instructions below to fill out Discovery of Galangin as a Potential DPP-4 Inhibitor That online quickly and easily:

Log in to your account. Sign up with your email and password or create a free account to test the service before upgrading the subscription.
Import a form. Drag and drop the file from your device or import it from other services, like Google Drive, OneDrive, Dropbox, or an external link.
Edit Discovery of Galangin as a Potential DPP-4 Inhibitor That. Easily add and underline text, insert pictures, checkmarks, and signs, drop new fillable areas, and rearrange or delete pages from your document.
Get the Discovery of Galangin as a Potential DPP-4 Inhibitor That completed. Download your modified document, export it to the cloud, print it from the editor, or share it with other people through a Shareable link or as an email attachment.

Benefit from DocHub, one of the most easy-to-use editors to quickly handle your paperwork online!

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.

Which is the best DPP-4 inhibitor?

Linagliptin is most effective in the inhibition of enzyme as compared to other DPP-4 inhibitors. The prolonged action is directly related to the strength and reversibility of binding to the enzyme (Ligueros-Saylan et al., 2010).

What is the function of the DPP IV enzyme?

DPP4 plays a major role in glucose metabolism. It is responsible for the degradation of incretins such as GLP-1. Furthermore, it appears to work as a suppressor in the development of some tumors. DPP-4 also binds the enzyme adenosine deaminase specifically and with high affinity.

What is a DPP-4 inhibitor with a GLP-1 agonist?

A combination with GLP-1 receptor agonists is not recommended since DPP-4 inhibitors as well as GLP-1 receptor agonists elevate GLP-1 plasma concentrations. DPP-4 inhibitors increase the endogenous GLP-1 concentrations ~2-3-fold, GLP-1 receptor agonists lead to 8-10-fold concentrations.

What is the main function of DPP-4?

DPP4 Functions DPP4 plays an important role in regulating body metabolism since it cleaves and inactivates peptides, such as glucagon-like peptide-1 (GLP-1), incretin hormones, and glucose-dependent insulinotropic polypeptide (GIP).

What does DPP-4 inhibitors do?

DPP-4 inhibitors lower blood sugar by helping the body increase the level of the hormone insulin after meals. Insulin helps move sugar from the blood into the tissues so the body can use the sugar to produce energy and keep blood sugar levels stable.

What does the inhibition of DPP-4 enzyme lead to?

The mechanism of DPP-4 inhibitors is to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying, and decreases blood glucose levels.

Which substance do DPP-4 inhibitors inhibit?

Gastrointestinal side effects and weight loss are frequent accompaniments of therapy with GLP-1 receptor agonists. The other class of pharmacotherapeutic agents that use the incretin system are DPP-4 inhibitors, which inhibit the principal enzyme responsible for the degradation of endogenous GLP-1.

What is the primary target of the DPP-4 enzyme that is inhibited by DPP-4 inhibitors?

Dipeptidyl-peptidase IV (DPP-4) inhibitors inhibit the degradation of the incretins, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).